MedTrace Logo

COVID-19 Convalescent Plasma (CCP) Transfusion

NCT04412486 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-11-29

No results posted yet for this study

Summary

This research study evaluates the safety and effectiveness for the use of convalescent plasma transfusion as a treatment option for novel coronavirus SARS-CoV-2 infection (COVID-19). Donors who have recovered from COVID-19 with high antibody levels to the CoV-2 virus will donate plasma at a Mississippi Blood Services facility. Recipients with COIVD-19 who have severe or life threatening conditions will receive plasma from those persons who have recovered from COVID-19.

Conditions

Interventions

BIOLOGICAL

COVID Convalescent Plasma

One unit of COVID Convalescent Plasma transfused on Day 0

Sponsors & Collaborators

  • University of Mississippi Medical Center

    collaborator OTHER

  • Gailen D. Marshall Jr., MD PhD

    lead OTHER

Principal Investigators

  • Gailen D Marshall, Jr., MD, PhD · University of Mississippi Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-03-23
Completion
2023-03-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04412486 on ClinicalTrials.gov